6 recruiting, 5 completed, 4 active not recruiting, 2 enrolling by invitation. 12 Phase 2, 7 Phase 3, 5 Phase 1, 1 Not applicable.
Follow Biohaven Therapeutics Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease BHV-1300, Placebo - Graves Disease | Phase 3 | Recruiting | Biohaven Therapeutics Ltd. | 300 | 2026-06-26 | 2026-10-19 |
| A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy BHV-1400, Placebo - IgA Nephropathy | Phase 3 | Not yet recruiting | Biohaven Therapeutics Ltd. | 420 | 2026-06-01 | 2026-06-11 |
| A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia BHV-7000, Placebo - Familial Erythromelalgia | Phase 1 | Enrolling by invitation | Biohaven Therapeutics Ltd. | 5 | 2026-01-15 | 2026-04-08 |
| Taldefgrobep Alfa in Adults With Overweight and Obesity Taldefgrobep Alfa, Placebo - Obesity, Overweight | Phase 2 | Active not recruiting | Biohaven Therapeutics Ltd. | 150 | 2025-11-24 | 2026-03-20 |
| Study of BHV-1300 in Graves' Disease BHV-1300 - Graves Disease | Phase 1 | Recruiting | Biohaven Therapeutics Ltd. | 15 | 2025-08-21 | 2026-07-31 |
| Study of BHV-1400 in IgA Nephropathy BHV-1400 - IgA Nephropathy | Phase 1 | Recruiting | Biohaven Therapeutics Ltd. | 20 | 2025-07-30 | 2026-06-23 |
| A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease BHV-8000 10mg, BHV-8000 20 mg, Placebo - Parkinson Disease | Phase 2 / Phase 3 | Recruiting | Biohaven Therapeutics Ltd. | 550 | 2025-05-28 | 2026-10-22 |
| A Phase 1 Study of BHV-1530 in Advanced Solid Tumors BHV-1530, Cemiplimab - Solid Tumor | Phase 1 | Recruiting | Biohaven Therapeutics Ltd. | 140 | 2025-03-20 | 2026-07-09 |
| Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine BHV-2100, Placebo - Migraine | Phase 2 | Completed | Biohaven Therapeutics Ltd. | 647 | 2024-10-10 | 2026-02-25 |
| Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD) BHV-7000 - Major Depressive Disorder | Phase 2 | Completed | Biohaven Therapeutics Ltd. | 233 | 2024-08-01 | 2026-10-14 |
| Long-term Safety and Tolerability of BHV-7000 BHV-7000 - Focal Epilepsy | Phase 2 | Enrolling by invitation | Biohaven Therapeutics Ltd. | 660 | 2024-07-30 | 2026-05-01 |
| BHV-7000 Open-Label Extension Bipolar Mania Study BHV-7000 - Bipolar Disorder | Phase 2 | Terminated | Biohaven Therapeutics Ltd. | 94 | 2024-06-24 | 2025-12-16 |
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures BHV-7000, Placebo - Generalized Epilepsy | Phase 2 / Phase 3 | Terminated | Biohaven Therapeutics Ltd. | 27 | 2024-06-20 | 2026-03-24 |
| Acceptability, Feasibility, Safety and Efficacy of a Optimized Rehabilitation Program for Treated Patients With Spinal Muscular Atrophy (SMA). Optimized rehabilitation program - Spinal Muscular Atrophy | Not applicable | Completed | University of Oxford | 14 | 2024-06-01 | 2026-09-15 |
| Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression BHV-7000, Placebo - Major Depressive Disorder | Phase 2 | Completed | Biohaven Therapeutics Ltd. | 336 | 2024-05-28 | 2026-10-14 |
| BHV-7000 Acute Treatment of Bipolar Mania BHV-7000, Placebo - Bipolar Disorder | Phase 2 / Phase 3 | Completed | Biohaven Therapeutics Ltd. | 274 | 2024-05-28 | 2025-12-16 |
| Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy BHV-7000, Placebo - Focal Epilepsy | Phase 2 / Phase 3 | Active not recruiting | Biohaven Therapeutics Ltd. | 390 | 2024-05-13 | 2026-08-13 |
| A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors BHV-1510, Cemiplimab - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Biohaven Therapeutics Ltd. | 500 | 2024-04-22 | 2026-09-28 |
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy BHV-7000, Placebo - Focal Epilepsy | Phase 2 / Phase 3 | Active not recruiting | Biohaven Therapeutics Ltd. | 390 | 2024-03-14 | 2026-09-30 |
| Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control BHV-4157 - Spinocerebellar Ataxias | Active not recruiting | Biohaven Therapeutics Ltd. | 909 | 2019-03-18 | 2026-06-09 |
Drug Resistant Epilepsy (4) · Epilepsy (4) · Seizures (4) · Epilepsies, Partial (3) · Bipolar Disorder (2) · Depression (2) · Depressive Disorder, Major (2) · Glomerulonephritis (2) · Glomerulonephritis, IGA (2) · Graves Disease (2) · Hyperthyroidism (2) · Kidney Diseases (2) · Mania (2) · Nephritis (2) · Proteinuria (2)
cemiplimab (2)
United States (18) · United Kingdom (5) · Australia (4) · Poland (4) · Austria (3) · Belgium (3) · Finland (3) · France (3) · Germany (3) · Hungary (3) · Italy (3) · Netherlands (3) · Portugal (3) · Spain (3) · Argentina (2)
Charlotte Lilien (1)
2023 (4), 2025 (1)